AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04795414 — intervention group
Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 Vaccine(Vero Cell), Inactivated
Description: The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)
Study NCT06080620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy for breast cancer
Description: Modified radical mastectomy for breast cancer
Study NCT06080620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical mastectomy for breast cancer
Description: Modified radical mastectomy for breast cancer
Study NCT06080620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Description: neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）
Study NCT06080620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic treatment
Description: chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）
Study NCT06080620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systematic treatment
Description: chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）
Study NCT06504030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified-DEP
Description: For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.
Study NCT06193538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant NV-A01 adenovirus injection
Description: Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
Study NCT04772092 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: during the routine blood test, collection of additional blood samples:~* 1 x 5 mL heparinized tube for plasma collection and storage~* 1 heparinized 5 mL tube for immunophenotyping~* 4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation
Study NCT04772092 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: * clinical examination data~* test results to measure the degree of geriatric fatigability~* Frailty screening questionnaire for neoplasia patients (G8 score)
Study NCT06468644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy （CRT）+sintilimab 1
Description: radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
Study NCT06468644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRT+sintilimab 2
Description: radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
Study NCT04926753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Cisplatin, Toripalimab
Description: Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
Study NCT05295173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of recombinant human tissue plasminogen kinase derivatives
Description: 18mg/10ml/stick, provided by Angde Biotech
Study NCT05295173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human tissue plasminogen activator
Description: 20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
Study NCT04374474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory retraining
Description: Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.
Study NCT04374474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid nasal irrigation
Description: Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
Study NCT04374474 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: smell household Items
Description: Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items
Study NCT04374474 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nasal Irrigation
Description: Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
Study NCT06565585 — intervention group
Intervention type: PROCEDURE
Intervention: Glans-sparing surgery
Description: Patients who underwent glans-sparing surgery
Study NCT04374474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal Irrigation
Description: Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
Study NCT05054621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heterologous prime-boost schedule with AZD1222 and MVC-COV1901
Description: Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
Study NCT05054621 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Homologous prime-boost schedule with two doses of AZD1222
Description: Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
Study NCT05923333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis Rosell®-33
Description: B. infantis Rosell®-33 + maltodextrin
Study NCT05923333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT04954625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Blood Patch
Description: All patients will be assessed on the morning of postoperative Day 3 and 4 for the presence of an air leak. If an air leak is present, 60-100 ml of autologous blood will be drawn from a peripheral vein and immediately instilled into the chest tube. The individual who draws blood is that the discretion of the site principal investigator. The tubing will be elevated over an IV pole while the patient remains in bed, moving position every 15 minutes for 1 hour to distribute the blood throughout the pleural cavity. The tubing support will then be removed, allowing the chest tube to drain. After ABP intervention, the chest tube will remain to water seal, as long as the patient tolerates it.
Study NCT04841564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound approach of serratus anterior block
Description: After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.
Study NCT04841564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open approach of serratus anterior block
Description: After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
Study NCT05737641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water ingestion
Description: ingestion of water after an 8h-fasting period
Study NCT05737641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: jelly ingestion
Description: ingestion of jelly after an 8h-fasting period
Study NCT05592886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMT04 formula
Description: The SMT04 formula is a synbiotic containing probiotics and prebiotics
Study NCT05592886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active placebo
Description: The active placebo is 2 mg Vitamin C with an inert substance made of starch filler. The flavor, coloring and appearance are unidentifiable to the study product.
Study NCT04731441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise Program Prior to CRS-HIPEC
Description: Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
Study NCT04731441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Education
Description: Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
Study NCT05478174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 for induction of general anesthesia
Study NCT05478174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol for induction of general anesthesia.
Study NCT06444477 — intervention group
Intervention type: OTHER
Intervention: ITP and cancer
Description: ITP and cancer
Study NCT04954625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (per Physician)
Description: Patients randomized to Standard of Care will be treated as their surgeon would as routine. This may mean postoperative observation, of another type of intervention.
Study NCT05081323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-applied treatment for phobias
Description: The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
Study NCT05839665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Humidified high-flow nasal oxygen
Description: Humidified high-flow oxygen delivered via the Optiflow device
Study NCT05839665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard nasal cannula
Description: Oxygen delivered with high flows via a standard nasal cannula
Study NCT05839665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facemask
Description: Oxygen delivered with facemask
Study NCT05644327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular training (CT)
Description: 12 weeks of CT
Study NCT05644327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Description: 12 weeks of RT
Study NCT05644327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal training (MT)
Description: 12 weeks of MT
Study NCT04939623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probenecid
Description: The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
Study NCT04939623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probenecid
Description: The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
Study NCT06567665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: Leucine is a dietary supplement that can be easily purchased over the counter at health food stores. It is an essential amino acid and is involved in stimulate muscle protein synthesis.
Study NCT05357391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Pressure Injury Prediction and Education model using a mobile application system
Description: Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
Study NCT06716970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR12000 75mg
Description: QR12000 75mg QD
Study NCT05915026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846)
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study NCT05268250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R2D2 mHealth intervention
Description: R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
Study NCT06568471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lerodalcibep
Description: PCSK9 inhibitor
Study NCT06568471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: placebo
Study NCT06568614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2039
Description: SYH2039 dosed orally
Study NCT05415618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Description: Manual lymphatic drainage will be applied 5 days a week for about 15 minutes every day for 4 weeks.
Study NCT05415618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splint
Description: In splint treatment, a volar-supported splint that keeps the wrist in a neutral position will be preferred and it will be recommended to both groups to be used only at night for 4 weeks.
Study NCT05415618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve gliding
Description: Median nerve gliding exercises as a home exercise program will be performed by the patient 5 days a week for 4 weeks. It will be performed in 6 different consecutive positions of the hand and wrist.
Study NCT04776135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension
Study NCT03278639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation
Description: Training will be directed to ameliorate gait and balance
Study NCT03278639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiology
Description: Training will be directed to ameliorate gait and balance
Study NCT06716970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR12000 75mg placebo
Description: Matching placebo of QR12000 75mg QD
Study NCT06716970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QR12000 75mg placebo
Description: Matching placebo of QR12000 75mg QD
Study NCT05691426 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of pulse wave amplitude (PWA)
Description: Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)
Study NCT05691426 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Nitric Oxide
Description: assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,
Study NCT04964960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immunotherapy that can help fight certain cancers.
Study NCT05765968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Stimulation Protocol
Description: cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle
Study NCT05765968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antagonist Stimulation Protocol
Description: cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
Study NCT05735080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-315
Description: Oral administration
Study NCT05735080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be combined with INX-315
Study NCT05664997 — intervention group
Intervention type: BEHAVIORAL
Intervention: playing assessment
Description: Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
Study NCT04964960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.
Study NCT05789732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo treatment once daily.
Study NCT04964960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.
Study NCT04964960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.
Study NCT04964960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.
Study NCT05789732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Patients will receive Silodosin 8 mg once daily.
Study NCT05789732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Patients will receive Tadalafil 5 mg once daily.
Study NCT05789732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin and Tadalafil
Description: Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
Study NCT05596227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
Study NCT05596227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
Study NCT05596227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)